INHIBRX BIOSCIENCES INC

Company Overview

Inhibrx Biosciences, Inc. (INBX) is a clinical‑stage Biotechnology company in the Healthcare sector developing engineered single‑domain antibody and multivalent protein therapeutics, with lead programs ozekibart (INBRX‑109) for chondrosarcoma and INBRX‑106 (an OX40 agonist) being advanced alone and in combination with pembrolizumab. The company is R&D‑centric, outsources manufacturing to CMOs, maintains an active patent portfolio, and completed a May 2024 spin‑off/separation that materially reshaped its cost base and capital structure. Near‑term value drivers are registration‑enabling data for INBRX‑109 and Phase 2/3 progression and readouts for INBRX‑106 (multiple expected mid‑ to late‑2025 and Q4 2025).

Executive Compensation Practices

Compensation is likely equity‑heavy and milestone‑driven: management has signaled large one‑time accelerations of stock‑based awards tied to the May 2024 Merger/Separation, and ongoing incentive pay will almost certainly be linked to clinical and regulatory milestones (data readouts, Phase transitions, approvals) and fundraising outcomes. Given the company’s modest revenues, cash burn and reliance on additional capital, base salaries are probably modest relative to long‑term equity incentives and performance‑based bonuses; retention features (accelerated vesting or milestone grants) are also plausible given recent reorganization and key upcoming readouts. Contractual and accounting arrangements (stock‑based compensation treatment, potential repricing or replacement of awards after financings, and loan facility covenants) will materially affect reported G&A and executive pay expense.

Insider Trading Considerations

Insider trading patterns at INBX will be highly event‑driven: purchases or sales by insiders are most informative around clinical data releases (notably Oct 2025 chondrosarcoma and Q4 2025 INBRX‑106 updates), financing announcements (equity raises or use of the $100M loan facility) and transaction milestones tied to the 2024 separation. Expect robust blackout periods, Form 4/10b5‑1 plan usage, and possible lock‑ups or contractual trading restrictions stemming from the spin‑off and any collaboration agreements; the 2024 stock‑award accelerations also created atypical insider holdings and potential selling pressure. Operational dependencies (CDMO performance, FDA holds/adverse safety signals) can produce sudden, material insider activity—insider buys ahead of positive readouts are a stronger signal than opportunistic sales, which may reflect liquidity needs or diversification given the company’s limited cash runway and likely future dilution.